Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
New Epidermal Differentiation Disorders Classification as a Catalyst for Research and Future Therapies
Description
The speaker argues that the new epidermal differentiation disorders (EDD) classification is a major step forward because it replaces a fragmented, confusing set of terms with a more precise, less stigmatizing framework that better separates skin-limited from multisystem disease and links genetics, mechanisms, management, and future therapies. The classification объединяет more than 150 conditions, including previously uncategorized disorders, and has already inspired tools like an online database to improve access and clarity. Beyond terminology, it is acting as a catalyst for research by bringing clinicians and scientists working on related diseases together, encouraging shared symposia, data exchange, and international collaboration. The talk highlights a Delphi-driven process to define future priorities over the next five years, emphasizing international networks, genotype-phenotype studies, patient perspectives, age-appropriate diagnostics, guidelines, treatment-target discovery, drug repurposing, standardized outcome measures, psychosocial support, and quality of life. The speaker notes that personalized medicine and equitable global access remain important goals, even if some are not feasible soon, and concludes that the new classification is not just a naming system but a practical platform for advancing care, research, and therapies.
View moreConclusions
- The new epidermal differentiation disorders classification is valuable because it replaces fragmented, stigmatizing terminology with a more precise and clinically useful framework.
- Grouping these conditions together helps clinicians and researchers distinguish skin-limited from multisystem disease and communicate more clearly with patients and genetics teams.
- The reclassification is acting as a catalyst for collaboration by bringing previously separate disease communities and research groups into the same network.
- Shared disease mechanisms across EDDs make common research strategies, trial designs, and therapeutic approaches more feasible than treating each disorder in isolation.
- Future progress should focus on international collaboration, genotype-phenotype studies, and better inclusion of patient perspectives in research priorities.
- Improved diagnostic criteria and age-appropriate follow-up guidelines are needed, especially in regions where genetic testing is less accessible.
- Treatment development should prioritize identifying mechanism-based targets, repurposing existing drugs, and moving toward personalized therapies.
- A major next step is creating standardized core outcome measures so that trials across EDDs can be compared meaningfully.
- Long-term goals include equitable multidisciplinary care, better education, and coordinated access to treatment worldwide.
- The overall conclusion is that the new classification is not just a naming system but a practical platform for research, diagnostics, management, and future therapy development.
- Oji et al. JAAD 2010.
- Paller et al. Br J Derm 2025.
- Choate et al., Science 2010.
- Sprecher et al., under revision BJD.
- Gostynski et al. in preparation.
- Costynski et al. in preparation.
- Rossel and Borghouts et al., 2026 (under review).